NovoCure Limited (NVCR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 03:45PM EDT. Market open.
| Previous Close | 12.06 |
| Open | 12.09 |
| Bid | 12.18 x 600 |
| Ask | 12.31 x 500 |
| Day's Range | 12.02 - 12.39 |
| 52 Week Range | 10.87 - 83.60 |
| Volume | |
| Avg. Volume | 1,276,124 |
| Market Cap | 1.316B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.95 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.33 |
Business WireResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
ROOT, Switzerland, April 24, 2024--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.
Business WireNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
ROOT, Switzerland, April 05, 2024--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
ZacksNovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
© 2024 Yahoo. All rights reserved.